{"title":"补充维生素 D 对接受辅助化疗的 II-III 期结直肠癌患者生活质量的影响：单盲随机对照试验》。","authors":"Tovan Perinandika, Reno Rudiman, Andriana Purnama","doi":"10.1007/s12029-024-01142-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer is the third most common cancer with the second highest mortality worldwide in 2020. Adjuvant chemotherapy is given for stage II-III colorectal cancer. However, there are side effects that decrease the patient's quality of life. Several studies have found that vitamin D could reduce the side effects of chemotherapy, but studies at Hasan Sadikin Hospital have not been done.</p><p><strong>Methods: </strong>A study regarding the effect of vitamin D supplementation on the quality of life of stage II-III colorectal cancer patients undergoing adjuvant chemotherapy from May 2022 to April 2023 at Hasan Sadikin Hospital was conducted. A single-blinded, randomized controlled trial (RCT) with consecutive sampling was done at the digestive surgery outpatients. Data was taken from the medical record, history taking, and personal interviews. Quality of life was measured at the first, third, and sixth months after chemotherapy using the validated Indonesian version of the EORTC QLQ-C30 questionnaire.</p><p><strong>Results: </strong>A total of 34 patients received vitamin D and 34 others received placebo. Serum vitamin D levels significantly increased (p < 0.001) in the intervention arm, from a median of 21.34 (5.26-29.95) to 27.92 (13.58-40.49). Meanwhile, it decreased in the placebo arm, from a median of 22.78 (8.3-29.93) to 21.37 (7.45-31.26). The patient's quality of life improved significantly after receiving vitamin D, compared with the placebo group on the third (median of 75.0 vs 45.83) and sixth (median of 83.33 vs 33.33) months after chemotherapy.</p><p><strong>Conclusion: </strong>Vitamin D consumption (10,000 IU/day) could improve the quality of life of colorectal cancer patients undergoing adjuvant chemotherapy.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"22"},"PeriodicalIF":1.6000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effect of Vitamin D Supplementation on Quality of Life in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy: A Single-Blind, Randomized Controlled Trial.\",\"authors\":\"Tovan Perinandika, Reno Rudiman, Andriana Purnama\",\"doi\":\"10.1007/s12029-024-01142-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Colorectal cancer is the third most common cancer with the second highest mortality worldwide in 2020. Adjuvant chemotherapy is given for stage II-III colorectal cancer. However, there are side effects that decrease the patient's quality of life. Several studies have found that vitamin D could reduce the side effects of chemotherapy, but studies at Hasan Sadikin Hospital have not been done.</p><p><strong>Methods: </strong>A study regarding the effect of vitamin D supplementation on the quality of life of stage II-III colorectal cancer patients undergoing adjuvant chemotherapy from May 2022 to April 2023 at Hasan Sadikin Hospital was conducted. A single-blinded, randomized controlled trial (RCT) with consecutive sampling was done at the digestive surgery outpatients. Data was taken from the medical record, history taking, and personal interviews. Quality of life was measured at the first, third, and sixth months after chemotherapy using the validated Indonesian version of the EORTC QLQ-C30 questionnaire.</p><p><strong>Results: </strong>A total of 34 patients received vitamin D and 34 others received placebo. Serum vitamin D levels significantly increased (p < 0.001) in the intervention arm, from a median of 21.34 (5.26-29.95) to 27.92 (13.58-40.49). Meanwhile, it decreased in the placebo arm, from a median of 22.78 (8.3-29.93) to 21.37 (7.45-31.26). The patient's quality of life improved significantly after receiving vitamin D, compared with the placebo group on the third (median of 75.0 vs 45.83) and sixth (median of 83.33 vs 33.33) months after chemotherapy.</p><p><strong>Conclusion: </strong>Vitamin D consumption (10,000 IU/day) could improve the quality of life of colorectal cancer patients undergoing adjuvant chemotherapy.</p>\",\"PeriodicalId\":15895,\"journal\":{\"name\":\"Journal of Gastrointestinal Cancer\",\"volume\":\"56 1\",\"pages\":\"22\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-11-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Gastrointestinal Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12029-024-01142-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-024-01142-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
简介结直肠癌是第三大常见癌症，2020 年全球死亡率第二高。II-III期结直肠癌可采用辅助化疗。然而，化疗的副作用会降低患者的生活质量。有几项研究发现，维生素 D 可以减轻化疗的副作用，但哈桑-萨迪金医院尚未进行过此类研究：方法：2022 年 5 月至 2023 年 4 月，哈桑-萨迪金医院开展了一项关于补充维生素 D 对接受辅助化疗的 II-III 期结直肠癌患者生活质量影响的研究。该研究在消化外科门诊病人中进行了连续抽样的单盲随机对照试验（RCT）。数据来自病历、病史采集和个人访谈。在化疗后的第一、第三和第六个月，使用经过验证的印尼版 EORTC QLQ-C30 问卷测量患者的生活质量：共有34名患者接受了维生素D治疗，另有34名患者接受了安慰剂治疗。血清维生素 D 水平明显升高（P服用维生素 D（10,000 IU/天）可提高接受辅助化疗的结直肠癌患者的生活质量。
The Effect of Vitamin D Supplementation on Quality of Life in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy: A Single-Blind, Randomized Controlled Trial.
Introduction: Colorectal cancer is the third most common cancer with the second highest mortality worldwide in 2020. Adjuvant chemotherapy is given for stage II-III colorectal cancer. However, there are side effects that decrease the patient's quality of life. Several studies have found that vitamin D could reduce the side effects of chemotherapy, but studies at Hasan Sadikin Hospital have not been done.
Methods: A study regarding the effect of vitamin D supplementation on the quality of life of stage II-III colorectal cancer patients undergoing adjuvant chemotherapy from May 2022 to April 2023 at Hasan Sadikin Hospital was conducted. A single-blinded, randomized controlled trial (RCT) with consecutive sampling was done at the digestive surgery outpatients. Data was taken from the medical record, history taking, and personal interviews. Quality of life was measured at the first, third, and sixth months after chemotherapy using the validated Indonesian version of the EORTC QLQ-C30 questionnaire.
Results: A total of 34 patients received vitamin D and 34 others received placebo. Serum vitamin D levels significantly increased (p < 0.001) in the intervention arm, from a median of 21.34 (5.26-29.95) to 27.92 (13.58-40.49). Meanwhile, it decreased in the placebo arm, from a median of 22.78 (8.3-29.93) to 21.37 (7.45-31.26). The patient's quality of life improved significantly after receiving vitamin D, compared with the placebo group on the third (median of 75.0 vs 45.83) and sixth (median of 83.33 vs 33.33) months after chemotherapy.
Conclusion: Vitamin D consumption (10,000 IU/day) could improve the quality of life of colorectal cancer patients undergoing adjuvant chemotherapy.
期刊介绍：
The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
